Enrichment tools to better understand the types of circulating nucleosomes and their genome patterns in the plasma of dogs with lymphoma



Bourne, K¹, Miller, T¹, Jarvis, J¹, Butera, T², Kelly, TK², Davis, B¹, Wilson-Robles, H¹ Texas A&M University College of Veterinary Medicine & Biomedical Sciences¹; Volition America and Volition Veterinary Diagnostics²



Introduction

- ❖ Nucleosomes = most basic structural components of DNA
- Methods by which circulating nucleosomes are produced
 - Dying/activated WBCs
 - Apoptotic cells
 - Tumor cell secretion
- Elevated nucleosome levels in sepsis, severe burns, immune-mediated diseases, cancer
- ❖ H3.1 ELISA validated for measurement of nucleosome levels in canine lymphoma (LSA) patients
- ❖ H1 Nu.Q[®] Capture


AIM: To isolate and sequence cancer-derived nucleosomes from dogs diagnosed with LSA

Methods

Sample Collection




Nu.Q® Capture



Methods (cont.)






Results

Patient ID	Nucleosome Content (ng/mL)
Chester (c)	24.4
LSA (10016)	>2500
LSA (60010)	>2500

Figure 1: Plasma-derived nucleosome sequencing histograms. A: Sequencing histogram of lymphoma patient 10016 immunoprecipitated. B: Sequencing histogram of lymphoma-patient 10016 supernatant. C: Sequencing histogram of supernatant fraction highlighting enrichment of 147bp insert size. D: Sequencing histogram of control (healthy) patient supernatant fraction lacking the peak at 147bp.

Figure 2: Aneuploidy and copy number variation.

Depicting gain of chromosome 13, loss of chromosome 14, and potential gain of the q arm of chromosome 31 (highlighted panels). Other potential copy number variants exist across chromosomes.



Conclusions

- Canine lymphoma patients have circulating nucleosomes lacking linker DNA (i.e., shorter nucleosomes) that are not detected in plasma from healthy canines.
- ❖ The Nu.Q[®] Capture is capable of enriching canine cancer-associated nucleosomes in plasma of naïve multicentric lymphoma patients.
- ❖ These shorter, canine lymphoma-associated, nucleosomes demonstrate rare genetic variants, most notably gain of chromosome 13, loss of chromosome 14, and potential aberrations on chromosome 31.

References

- 1. Holdenrieder S, Nagel D, Schalhorn A, et al. Clinical relevance of circulating nucleosomes in cancer. Ann N Y Acad Sci 2008;1137:180-189.

 2. Bohers E, Viailly P-J, Becker S, et al. Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort.

 Blood Cancer Journal 2018:8.
- 3. Wilson-Robles H, Miller T, Jarvis J, et al. Evaluation of nucleosome concentrations in healthy dogs and dogs with cancer. PLOS ONE 2020;15:e0236228.

 4. Dolan C, Miller T, Jill J, et al. Characterizing circulating nucleosomes in the plasma of dogs with lymphoma. BMC Veterinary Research 2021;17.
- 4.Dolan C, Miller T, Jill J, et al. Characterizing circulating nucleosomes in the plasma of dogs with lymphoma. BMC Veterinary Research 2021;17.

 5.Terrell J, Van den Ackerveken P, Lobbens A, et al. Enrichment of circulating tumor DNA from cell-free DNA of hematopoietic origin: American Society of Clinical Oncology, 2020; e13534-e13534

Future Directions

- Optimize Nu.Q® Capture assay for enhanced cancer-associated nucleosome enrichment.
- Deeper analysis of candidate genes and known drivers of canine lymphoma with the goal of identifying diagnostic and prognostic markers in a wider variety of lymphoma cases.
- Expansion of the Nu.Q® methodology and sequencing pipelines utilized in this study to additional canine cancers, including hemangiosarcoma and osteosarcoma.
- Combine H1 Nu.Q® Capture with additional assays to better understand cancer derived circulating nucleosomes

Acknowledgements

- Texas A&M University College of Veterinary Medicine Veterinary Small Animal Clinical Sciences Department
- ❖ Texas A&M University Department of Veterinary Integrative Biosciences
- Research in this study has been funded by Volition Veterinary Diagnostic Development.